Mechanism of Action
Calcitonin Receptor Signaling
Calcitonin binds calcitonin receptors (CTR, a class B GPCR) on osteoclasts, coupling to Gs (raising cAMP) and Gq (raising calcium). cAMP-mediated effects include rapid retraction of the osteoclast ruffled border and loss of podosomes, physically detaching the osteoclast from bone surface. This "quiescence effect" reduces bone resorption within minutes. Prolonged exposure also reduces osteoclast formation and number.
Analgesic Mechanism
Calcitonin produces analgesia through mechanisms partly independent of bone effects. Calcitonin receptors are expressed in CNS pain-processing regions (periaqueductal gray, dorsal raphe, spinal dorsal horn). Analgesic effects involve beta-endorphin release, serotonin pathway modulation, and direct effects on cgrp/" class="wiki-internal-link">CGRP and substance P release. This explains efficacy in acute vertebral fracture pain and Paget bone pain beyond simple anti-resorptive effects.
Research Summary
Osteoporosis
FDA ApprovedPROOF trial (nasal calcitonin 200 IU/day): 36% reduction in new vertebral fractures over 5 years. No significant hip fracture reduction. CHMP 2012 review raised concerns about rare malignancy signal with long-term use (oral/nasal), leading to label changes. Salmon calcitonin injection retains approval; nasal spray label updated with cancer risk caveat. Bisphosphonates and denosumab have largely replaced calcitonin for osteoporosis prevention.
Acute Vertebral Fracture Pain
Well EstablishedMultiple trials demonstrate significant pain reduction with SC calcitonin 100-200 IU daily for acute osteoporotic vertebral fractures, particularly within the first 4-6 weeks when pain is most severe. Cochrane review confirms analgesic efficacy. Used as short-term bridge therapy while fracture healing proceeds or other treatments are initiated.
Paget Disease
FDA ApprovedCalcitonin normalizes elevated alkaline phosphatase and reduces bone pain in Paget disease. SC 50-100 IU daily or alternate day regimens. Bisphosphonates are now first-line for Paget due to greater potency and convenience, but calcitonin remains an option when bisphosphonates are contraindicated.
Calculate your Calcitonin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Postmenopausal osteoporosis | 200 IU intranasal daily (alternating nostrils) or 100 IU SC/IM every other day | Daily (intranasal) or alternate days (SC) | Intranasal or subcutaneous |
| Acute hypercalcemia | 4 IU/kg SC or IM every 12 hours; may increase to 8 IU/kg every 6 hours if inadequate response | Every 6-12 hours | Subcutaneous or intramuscular |
| Acute vertebral fracture pain | 100-200 IU SC daily for 2-4 weeks | Daily short course | Subcutaneous |
Skin test recommended before initiation due to allergy risk with salmon protein. Resistance (antibody formation) may develop with long-term use. Nasal spray: alternate nostrils daily.
Interactions
Safety Profile
Common: nausea and facial flushing (15-20% with injection; less with nasal spray), injection site reactions. Nasal spray: rhinitis, nasal dryness, epistaxis in approximately 10-12% of users. Hypocalcemia possible, especially with pre-existing vitamin D deficiency. Long-term risk: FDA/EMA raised concerns about increased cancer incidence (particularly nasal spray forms) from pooled trial data; absolute risk appears small but label includes warning. Antibody formation can occur with long-term salmon CT use, reducing efficacy. Rare anaphylaxis; skin test before injection initiation recommended.
References
- [1]Chesnut CH 3rd, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis (PROOF). Am J Med. 2000;109(4):267-276.
- [2]Knopp-Sihota JA, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review. Osteoporos Int. 2012;23(1):17-38.